Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Related REGN
3 Biotech ETFs Rally On Merger News
A Look At 3 Overbought ETFs
Making Money With Charles Payne: 12/22/14 (Fox Business)
Related AGN
Ackman: Allergan Is A Good Merger Arbitrage Play, Potential 28% Upside
Benzinga's Top Downgrades
Energy Sector Seen as Biggest Risk to Deal Flow in 2015 (Fox Business)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Nov 2014Bank of AmericaMaintainsBuy
Nov 2014Brean CapitalMaintainsBuy
Nov 2014Argus ResearchMaintainsBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

Around the Web, We're Loving...

Get Benzinga's Newsletters